Antibody Drug Conjugates (ADCS) Market
Antibody Drug Conjugates (ADCS) Market - Global Industry Assessment & Forecast
#
Pages:
155
Base Year:
2022
Feb - 2022
Format:
Report Code:
VMR-1280
Segments Covered
By
Application Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer, Blood Cancer
-
By
Technology Cleavable Linker, Non-Cleavable Linker, Linkerless
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 4.75 Billion |
 Revenue 2030:
|
USD 18.84 Billion |
 Revenue CAGR
(2023 - 2030): |
18.80% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Antibody Drug Conjugates (ADCS) Market Segment Analysis
- Antibody Drug Conjugates (ADCS) Application Outlook (Revenue, USD Million, 2018 - 2030)
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Antibody Drug Conjugates (ADCS) Technology Outlook (Revenue, USD Million, 2018 - 2030)
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
-
North America Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- U.S.
- U.S. Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- U.S. Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- U.S. Antibody Drug Conjugates (ADCS) Market, by Application
- Canada
- Canada Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Canada Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Canada Antibody Drug Conjugates (ADCS) Market, by Application
-
Mexico
- Mexico Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Mexico Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Mexico Antibody Drug Conjugates (ADCS) Market, by Application
-
North America Antibody Drug Conjugates (ADCS) Market, by Application
- Europe
-
Europe Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
-
Europe Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- U. K.
- U.K. Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- U.K. Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- U.K. Antibody Drug Conjugates (ADCS) Market, by Application
- France
- France Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- France Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- France Antibody Drug Conjugates (ADCS) Market, by Application
-
Germany
- Germany Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Germany Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Germany Antibody Drug Conjugates (ADCS) Market, by Application
-
Italy
- Italy Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Italy Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Italy Antibody Drug Conjugates (ADCS) Market, by Application
-
Spain
- Spain Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Spain Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Spain Antibody Drug Conjugates (ADCS) Market, by Application
-
Rest of Europe
- Rest of Europe Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Rest of Europe Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Rest of Europe Antibody Drug Conjugates (ADCS) Market, by Application
-
Europe Antibody Drug Conjugates (ADCS) Market, by Application
- Asia Pacific
-
Asia Pacific Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
-
Asia Pacific Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- China
- China Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- China Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- China Antibody Drug Conjugates (ADCS) Market, by Application
- Japan
- Japan Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Japan Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Japan Antibody Drug Conjugates (ADCS) Market, by Application
-
Germany
- Germany Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Germany Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Germany Antibody Drug Conjugates (ADCS) Market, by Application
-
India
- India Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- India Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- India Antibody Drug Conjugates (ADCS) Market, by Application
-
South Korea
- South Korea Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- South Korea Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- South Korea Antibody Drug Conjugates (ADCS) Market, by Application
-
South East Asia
- South East Asia Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- South East Asia Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- South East Asia Antibody Drug Conjugates (ADCS) Market, by Application
-
Rest of Asia Pacific
- Rest of Asia Pacific Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Rest of Asia Pacific Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Rest of Asia Pacific Antibody Drug Conjugates (ADCS) Market, by Application
-
Asia Pacific Antibody Drug Conjugates (ADCS) Market, by Application
- Latin America
-
Latin America Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
-
Latin America Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Brazil
- Brazil Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Brazil Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Brazil Antibody Drug Conjugates (ADCS) Market, by Application
- Argentina
- Argentina Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Argentina Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Argentina Antibody Drug Conjugates (ADCS) Market, by Application
-
Rest of Latin America
- Rest of Latin America Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Rest of Latin America Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Rest of Latin America Antibody Drug Conjugates (ADCS) Market, by Application
-
Latin America Antibody Drug Conjugates (ADCS) Market, by Application
- Middle East & Africa
-
Middle East & Africa Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
-
Middle East & Africa Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- GCC Countries
- GCC Countries Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- GCC Countries Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- GCC Countries Antibody Drug Conjugates (ADCS) Market, by Application
- South Africa
- South Africa Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- South Africa Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- South Africa Antibody Drug Conjugates (ADCS) Market, by Application
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Antibody Drug Conjugates (ADCS) Market, by Application
- Breast Cancer
- Urothelial Cancer & Bladder Cancer
- Other Cancer
- Blood Cancer
- Rest of Middle East & Africa Antibody Drug Conjugates (ADCS) Market, by Technology
- Cleavable Linker
- Non-Cleavable Linker
- Linkerless
- Rest of Middle East & Africa Antibody Drug Conjugates (ADCS) Market, by Application
-
Middle East & Africa Antibody Drug Conjugates (ADCS) Market, by Application
- North America
Vantage Market
Research | 09-Feb-2022
FAQ
Frequently Asked Question
What is the global demand for Antibody Drug Conjugates (ADCS) in terms of revenue?
-
The global Antibody Drug Conjugates (ADCS) valued at USD 4.75 Billion in 2022 and is expected to reach USD 18.84 Billion in 2030 growing at a CAGR of 18.80%.
Which are the prominent players in the market?
-
The prominent players in the market are Takeda Pharmaceutical Company Ltd. (Japan), F. Hoffmann-La Roche Ltd. (US), Pfizer Inc. (US), AstraZeneca (Sweden), Gilead Sciences Inc. (US), Astellas Pharma (Japan), Seagen Inc. (US), Daiichi Sankyo Company Ltd. (Japan), GlaxoSmithKline PLC (UK), ADC Therapeutics (Switzerland).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 18.80% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Antibody Drug Conjugates (ADCS) include
- Significant Investment in Research and Development
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Antibody Drug Conjugates (ADCS) in 2022.
